No Yes Ok

Archive

« Older Entries Newer Entries »

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia Friday, March 31st, 2017
Breda, the Netherlands / Ghent, Belgium, March 31, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases Tuesday, March 21st, 2017
Differentiated antibody to address complement target  Represents latest collaboration to stem from the argenx Innovative Access Program  argenx granted option to license program after preclinical pro [...]
Merus Named BioCapital Europe 2017 Company of the Year Thursday, March 16th, 2017
Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months   UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-o [...]
LSP invests in Orphazyme as part of a EUR 14 million Series B extension to further expand clinical programmes Wednesday, March 15th, 2017
Amsterdam, The Netherlands, March 15, 2017 - LSP portfolio company Orphazyme ApS announced today the completion of a EUR 14 million financing round. Together with the ALS Investment Fund, LSP joins the investor syndic [...]
argenx reports fourth quarter business update and full year 2016 financial results Wednesday, March 15th, 2017
Breda, the Netherlands / Ghent, Belgium, March 15, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
LSP takes part in Euronext Amsterdam gong ceremony Tuesday, March 14th, 2017
BioCapital Europe, an LSP healthcare conference, will take place for the 15th time in Amsterdam. Geraldine O’Keeffe, Partner at LSP and conference host, sounds the gong in recognition of the 15th anniversary of the [...]
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia Monday, March 6th, 2017
Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia- Represents latest collaboration to stem from the argenx's Innovative Access Program- argenx is eligible to receive a [...]
argenx announces intention to conduct a registered public offering in the United States Wednesday, March 1st, 2017
Breda, the Netherlands / Ghent, Belgium, March 1, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Kuros receives clearance from the US FDA for MagnetOs allowing marketing in the United States Monday, February 27th, 2017
Schlieren (Zurich), Switzerland, February 27, 2017 - Kuros Biosciences (SIX: KURN) announces today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Granules. FDA’s a [...]
argenx announces extension of therapeutic antibody alliance with Shire Monday, February 27th, 2017
Breda, the Netherlands / Ghent, Belgium, February 27, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treat [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia Friday, March 31st, 2017
Breda, the Netherlands / Ghent, Belgium, March 31, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases Tuesday, March 21st, 2017
Differentiated antibody to address complement target  Represents latest collaboration to stem from the argenx Innovative Access Program  argenx granted option to license program after preclinical pro [...]
Merus Named BioCapital Europe 2017 Company of the Year Thursday, March 16th, 2017
Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months   UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-o [...]
LSP invests in Orphazyme as part of a EUR 14 million Series B extension to further expand clinical programmes Wednesday, March 15th, 2017
Amsterdam, The Netherlands, March 15, 2017 - LSP portfolio company Orphazyme ApS announced today the completion of a EUR 14 million financing round. Together with the ALS Investment Fund, LSP joins the investor syndic [...]
argenx reports fourth quarter business update and full year 2016 financial results Wednesday, March 15th, 2017
Breda, the Netherlands / Ghent, Belgium, March 15, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
LSP takes part in Euronext Amsterdam gong ceremony Tuesday, March 14th, 2017
BioCapital Europe, an LSP healthcare conference, will take place for the 15th time in Amsterdam. Geraldine O’Keeffe, Partner at LSP and conference host, sounds the gong in recognition of the 15th anniversary of the [...]
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia Monday, March 6th, 2017
Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia- Represents latest collaboration to stem from the argenx's Innovative Access Program- argenx is eligible to receive a [...]
argenx announces intention to conduct a registered public offering in the United States Wednesday, March 1st, 2017
Breda, the Netherlands / Ghent, Belgium, March 1, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Kuros receives clearance from the US FDA for MagnetOs allowing marketing in the United States Monday, February 27th, 2017
Schlieren (Zurich), Switzerland, February 27, 2017 - Kuros Biosciences (SIX: KURN) announces today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Granules. FDA’s a [...]
argenx announces extension of therapeutic antibody alliance with Shire Monday, February 27th, 2017
Breda, the Netherlands / Ghent, Belgium, February 27, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treat [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund